Earnings Feed
Start Free
Home/Filings/4/0001493152-22-021184
4//SEC Filing

Yen Yun 4

Accession 0001493152-22-021184

CIK 0001335105other
View on SEC.govCompany Profile

Filed

Aug 2, 8:00 PM ET

Accepted

Aug 3, 4:47 PM ET

Size

11.7 KB

Accession

0001493152-22-021184

Insider Transaction Report

Form 4
Period: 2022-06-30
LIXTE BIOTECHNOLOGY HOLDINGS, INC.LIXT
Yen Yun
Director
Transactions
  • Award

    Options to Purchase Common Stock

    2022-06-30+100,000→ 100,000 total
    Exercise: $0.74From: 2022-06-30Exp: 2027-06-30→ Common (100,000 underlying)
Holdings

  • Options to Purchase Common Stock

    Exercise: $1.68From: 2018-08-04Exp: 2023-08-04→ Common (33,333 underlying)
    33,333

  • Options to Purchase Common Stock

    Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying)
    8,333

  • Options to Purchase Common Stock

    Exercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying)
    100,000

  • Warrants to Purchase Common Stock

    (indirect: By Sino-American Cancer FDD)
    Exercise: $5.70From: 2020-11-30Exp: 2025-11-30→ Common (52,632 underlying)
    52,632

  • Options to Purchase Common Stock

    Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying)
    50,000
Footnotes (1)
  • [F1]Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

→
Entity typeother

Related Parties

1
  • filerCIK 0001684584

Filing Metadata

Form type
4
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 4:47 PM ET
Size
11.7 KB
View on SEC.gov